Please login to the form below

Not currently logged in
Email:
Password:

Viaskin Peanut

This page shows the latest Viaskin Peanut news and features for those working in and with pharma, biotech and healthcare.

EU authorises Aimmune’s peanut allergy treatment Palforzia

EU authorises Aimmune’s peanut allergy treatment Palforzia

Aimmune’s potential rival, DBV Technologies, has not had as much success with getting its peanut allergy treatment approved. ... In August, DBV announced that it had received a complete response letter (CRL) from the US Food and Drug Administration (FDA

Latest news

  • FDA knocks back DBV’s peanut allergy therapy once again FDA knocks back DBV’s peanut allergy therapy once again

    drug. Like Palforzia, the rationale for Viaskin Peanut is to expose people with peanut allergy to small amounts of antigen over time to encourage the immune system to develop tolerance. ... Analysts at Baird have suggested that with a weaker clinical

  • Aimmune’s Palforzia is first peanut allergy drug cleared in US Aimmune’s Palforzia is first peanut allergy drug cleared in US

    When used in conjunction with peanut avoidance, Palforzia provides an FDA-approved treatment option to help reduce the risk of these allergic reactions in children with peanut allergy,” added Marks. ... California biotech Aimmune has been in a race to

  • Aimmune gets FDA panel backing for peanut allergy therapy Aimmune gets FDA panel backing for peanut allergy therapy

    Peanut allergies are the leading cause of death from food-induced allergic reactions in the US. ... DBV was forced to withdraw the US marketing application for its Viaskin Peanut patch product last December after the FDA expressed concerns about

  • DBV refiles peanut allergy immunotherapy in the US DBV refiles peanut allergy immunotherapy in the US

    Follows initial manufacturing concerns. DBV Technologies was hit hard a few months back when it was forced to pull its FDA filing for peanut allergy therapy Viaskin Peanut. ... This is an important milestone for DBV, as we are one step closer towards

  • Aimmune wins over ICER for peanut allergy product Aimmune wins over ICER for peanut allergy product

    for the 1.6m people with peanut allergy in the US, and presented its case at an ICER meeting yesterday. ... Aimmune is currently leading the race to bring a peanut allergy therapy to market, after its main rival DBV Technologies decided to withdraw the

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oxford PharmaGenesis

Oxford PharmaGenesis is an independently owned HealthScience communications consultancy, providing services to the healthcare industry, professional societies and patient groups....

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...